In a series of moves that some analysts called unexpected, Erasca, Inc. unveiled the in-licensing of two preclinical RAS-targeted cancer compounds, outlined a planned $160m public offering and said it was de-emphasizing three ongoing programs on 16 May. These decisions came little more than one week after the San Diego-based firm’s first quarter earnings call, with one analyst saying he was surprised by the announcements and saw both upside and downside in them.
Erasca Revamps With Two In-Licensings, $160m Follow-On Offering
The San Diego biotech is also de-emphasizing three ongoing targeted cancer therapy candidates and giving itself the flexibility to focus on RAS- or KRAS-targeting approaches.
